Emergency, Tianjin First Central Hospital, Tianjin, 300192, China.
First Center Clinic College of Tianjin Medical University, Tianjin, 300192, China.
Ann Hematol. 2024 Aug;103(8):2569-2589. doi: 10.1007/s00277-023-05488-9. Epub 2023 Oct 18.
There have been several clinical studies using chimeric antigen receptor (CAR)-T cell therapy for different hematological malignancies. It has transformed the therapy landscape for hematologic malignancies dramatically. Nonetheless, in acute myeloid leukemia (AML) and T cell malignancies, it still has a dismal prognosis. Even in the most promising locations, recurrence with CAR-T treatment remains a big concern. Oncolytic viruses (OVs) can directly lyse tumor cells or cause immune responses, and they can be manipulated to create therapeutic proteins, increasing anticancer efficacy. Oncolytic viruses have been proven in a rising number of studies to be beneficial in hematological malignancies. There are limitations that cannot be avoided by using either treatment alone, and the combination of CAR-T cell therapy and oncolytic virus therapy may complement the disadvantages of individual application, enhance the advantages of their respective treatment methods and improve the treatment effect. The alternatives for combining two therapies in hematological malignancies are discussed in this article.
已经有几项使用嵌合抗原受体（CAR）-T 细胞疗法治疗不同血液系统恶性肿瘤的临床研究。它极大地改变了血液系统恶性肿瘤的治疗格局。然而，在急性髓系白血病（AML）和 T 细胞恶性肿瘤中，它的预后仍然很差。即使在最有希望的部位，CAR-T 治疗后的复发仍然是一个大问题。溶瘤病毒（OV）可以直接裂解肿瘤细胞或引起免疫反应，并且可以对其进行改造以产生治疗性蛋白，从而提高抗癌疗效。越来越多的研究已经证明溶瘤病毒对血液系统恶性肿瘤有益。这两种治疗方法单独使用都有无法避免的局限性，CAR-T 细胞疗法和溶瘤病毒疗法的联合应用可能可以互补各自应用的缺点，增强各自治疗方法的优势，提高治疗效果。本文讨论了血液系统恶性肿瘤中联合两种疗法的选择。
